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Abstract
Over the past 30 years, a plethora of pathogenic mutations affecting enhancer regions and epigenetic regulators
have been identified. Coupled with more recent genome-wide association studies (GWAS) and epigenome-wide
association studies (EWAS) implicating major roles for regulatory mutations in disease, it is clear that epigenetic
mechanisms represent important biomarkers for disease development and perhaps even therapeutic targets. Here,
we discuss the diversity of disease-causing mutations in enhancers and epigenetic regulators, with a particular
focus on cancer.
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Introduction
The modern polymath Conrad H Waddington
(1905–1975) was the first to coin the term ‘epige-
netics’ to describe heritable changes in gene expression
not caused by changes in the DNA sequence [1]. Now,
we know that the DNA is segregated into chromosomes
inside the nucleus of each cell and that packaging
proteins, called histones, associate with DNA to form
the chromatin. Nucleosomes are the basic units of
the chromatin and are formed by an octamer of his-
tones (two copies of a tetramer; H2A, H2B, H3, and
H4). If the DNA is well packed in these nucleosomes
(condensed chromatin), genes will be switched off,
whereas if the DNA is uncovered, as in decondensed
chromatin, and thus more accessible to transcription
factors (TFs), genes are more likely to be switched on.
The level of compaction of these nucleosomes is influ-
enced by chemical tags or ‘epigenetic modifications’,
which associate with the histones or directly with the
DNA. Just as each organism has its own unique DNA
sequence, each cell type at each developmental stage
has a distinctive epigenetic modification profile. As
such, cellular commitment and differentiation are by
definition an epigenetic phenomenon [2]. Critically,
the presence of these epigenetic modifications can be
associated with changes in the environment (eg diet,
stress, smoke inhalation, etc).
Genetic diseases are caused by a variety of mutations
affecting the genes or the regulatory regions (promoters,
enhancers, etc) controlling the expression of these genes,
as well as by chromosomal alteration, such as translo-
cations or aneuploidy. Enhancers are regulatory regions
that increase the rate or the probability of transcription
of a target gene. An enhancer may lie far away, upstream
or downstream from the gene that it regulates or may be
located in an intron of its target gene [3,4]. Mutations
of enhancer sequences, and of the protein factors regu-
lating enhancer function, contribute to a growing class
of ‘enhanceropathies’ [5]. α- and β-thalassaemia are key
examples ofmonogenic diseases which can be caused by
the deletion of remote enhancers in certain patients [6].
Epigenetic alterations including DNA methylation
and histone post-translational modifications are catal-
ysed by families of epigenetic regulators such as DNA
and histone methyltransferases. Only five DNA mod-
ifications have been identified in eukaryotes, whereas
approximately 130 specific histone modifications have
been described, grouped into 16 classes [7–9]. These
histone modifications involve many different amino
acids on each histone protein and have specific func-
tions [7,8]. Epigenetic modifications can be generated
by ‘writer’ enzymes and removed by ‘eraser’ enzymes.
Specialized ‘reader’ proteins contain unique domains
that specifically recognize these modifications and use
them as docking sites [10]. Some epigenetic regulators
are required for transcriptional regulation, DNA repair,
cell cycle, and differentiation – hence their important
role in many cancers.
Multigenic diseases (eg cancer) result from the accu-
mulation of mutations in genes such as oncogenes
(gain-of-function mutations) and/or tumour suppressor
genes (loss-of-function mutations). This causes a loss of
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coordination between proliferation and differentiation of
progenitor cells. Diseases involving mutations of epige-
netic regulators have been recently described in a variety
of solid tumours and blood malignancies [8]. This has
highlighted the importance of epigenetics in disease, but
also implies that these diseases are genetic after all.
In this review, we will discuss the complexity of
pathogenic mutations and single nucleotide polymor-
phisms (SNPs) affecting enhancer activity. Next, we will
look at the importance of epigenetic signatures that are
associatedwith diseases as biomarkers for disease devel-
opment. We will then discuss the role that epigenetic
regulator mutations play in disease and the interplay of
these genetic mutations and pure epigenetic mutations.
Although unique research advantages become available
when studying different model organisms it is important
to note the fundamental differences in the epigenetic reg-
ulation between different species, which we will discuss
throughout this review.
The molecular basis of aberrant gene expression
The effects of loss- and gain-of-function mutations can
be quantitative or qualitative. These are summarized
in Figure 1. The nature of a disease-inducing mutation
greatly influences the types of tests needed to diag-
nose and the therapeutic approaches used. A quantitative
change directly causes an increase or a decrease in abun-
dance of the final gene product. Quantitative changes
in expression are relatively easily detected with classi-
cal and low-cost techniques such as immunohistochem-
istry (IHC), fluorescence in situ hybridization (FISH),
colorimetric in situ hybridization (CISH), and real-time
quantitative polymerase chain reaction (qPCR) [11].
Qualitative changes can alter the function of a mutated
gene. Their detection may require more sophisticated
and high-cost sequencing techniques such as targeted
exome sequencing or whole genome sequencing (which
can now be achieved at a single cell level) [12–14].
However, when a qualitative mutation occurs in a master
regulator, this often influences the transcription levels of
downstream target genes, which can be measured using
quantitative means. For example, acute lymphoblastic
leukaemia (ALL) patients with MLL rearrangements
(discussed below) have a distinct gene expression pro-
file which distinguishes them from other ALL patients
and acute myeloid leukaemia (AML) patients [15].
Transcriptional enhancers and diseases
Loss-of-function enhancer mutations
Thirty years ago, human genetics studies pioneered the
identification of functional remote regulatory elements
in patients with α- and β-thalassaemia (reviewed in
ref 6). In most cases, a deletion removing a globin
gene causes its down-regulation (Figure 1C). However,
in rare cases, the genes (including their promoters)
remain intact but the deletion of one (or several) remote
enhancer(s) causes their down-regulation (Figure 1D).
There are many other instances in which enhancer
deletions have been shown to cause pathologies. Dele-
tions in enhancers of FOXL2 [16], POU3F4 [17],
SOST [18,19], and SOX10 [20,21] have been linked to
blepharophimosis syndrome, X-linked deafness type 3,
van Buchem disease, and Waardenburg syndrome type
4, respectively.
Deletions are not the only mutations affecting
enhancer function. Although the exact mechanism of
pathogenesis is currently unclear, a variety of SNPs
can affect enhancer activity by changing TF bind-
ing affinity and/or specificity (Figures 1B and 1I).
Hirschsprung disease (HSCR), a multigenic, heritable
disorder affecting the ganglion cells in the large intes-
tine or gastrointestinal tract, is an example. Less than
30% of HSCR patients have identified mutations in
the coding sequence of candidate genes, such as RET
(encoding a tyrosine kinase receptor), but SNPs within
the enhancers of either the SOX10 (a transcription factor
regulating RET expression) or the RET genes have been
identified in other patients [20–22]. SNPs in SOX10
enhancers in isolated HSCR and Waardenburg syn-
drome type 4 patients (a rare condition characterized by
deafness and pigmentation anomalies) have been shown
to significantly reduce Sox10 expression, also leading
to down-regulation of RET expression [20,21]. A single
base-pair change in one of the RET enhancers is also
overrepresented in affected populations [22]. This SNP
reduces the activity of the enhancer in gene reporter
assays compared with the normal allele, apparently by
disruption of a SOX10 binding site which subsequently
reduces RET expression [23].
Gain-of-function enhancer mutations
One example of gain-of-function pathogenic mutations
identified in enhancer sequences is in patients with
preaxial polydactyly [24,25]. Point mutations in the
long-distant, limb-specific enhancer for sonic hedgehog
(SHH) can cause ectopic expression of this gene, lead-
ing to the formation of extra digits in human and other
animal patients [26].
More recently, high-throughput sequencing technol-
ogy has allowed GWAS to identify a large number
of candidate SNPs associated with diseases [27,28].
A number of independent GWAS have identified dis-
tinct breast, prostate, and colon cancer risk regions in
the 8q24 region, each enriched with histone modifica-
tions that are characteristic of enhancers [29]. Within
these enhancer regions, various SNPs have been iden-
tified and that predispose susceptibility to certain can-
cer types. For example, the prostate cancer risk allele
rs11986220 exhibits stronger binding to the TF fork-
head box protein A1 (FOXA1) [30]. This increased
binding of FOXA1 can facilitate the recruitment of
FOXA1-dependent androgen receptor, which is associ-
ated with poor prognosis in prostate cancer [31].
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Figure 1. Molecular basis of genetic diseases. Effects of loss- and gain-of-function mutations affecting gene expression are quantitative
and/or qualitative. (A) A missense mutation or a small insertion/deletion mutation (frameshift) in a coding sequence or at a PolyA signal often
leads to abortive translation or RNA decay [162]. (B) Reduction of chromosomal looping between the enhancer and the promoter might be
due to (1) natural variant or mutation at the enhancer [163], (2) the presence of a new SNP forming a new enhancer/promoter region which
titrates the remote enhancer activity [43], or (3) promoter or enhancer hypermethylation [164]. (C) Deletion of the gene [165]. (D) Deletion
of the remote enhancer [166]. (E) Deletion of the PolyA signal of a downstream and convergent gene, leading to the production of antisense
RNA [167]. (F) Nonsense mutation adding a new premature stop codon producing a truncated protein [168]. Note that truncated proteins
may also have a gain-of-function activity [169]. (G) Missense mutation affecting the non-enzymatic activity or abolishing the catalytic
domain of an enzyme [104]. (H) Normal rate of transcription, but increased accumulation of final gene product due to the presence of an
RNA [170] or a protein [171] stabilizing molecule. (I) Increased enhancer activity due to (1) enhancer mutation [25], (2) overexpression of a
transcription factor [172], or (3) promoter hypomethylation [173]. (J) An increase in gene copy number, including regulatory regions [174].
(K) Large genomic deletion bringing a strong (but irrelevant) enhancer closer [175]. (L) Translocation with a heterologous chromosome (red)
creating a fusion locus with a new strong enhancer regulating an illegitimate gene [176]. (M) Translocation with a heterologous chromosome
(red) producing a fusion gene, with increased biological activity [96]. (N) Missense mutation improving enzymatic activity [81]. E, enhancer;
P, promoter; C, coding region; TF, transcription factor; CD, catalytic domain; MS, missense mutation; NS, nonsense mutation; FS, frameshift
mutation. Dashed curved arrows represent impaired enhancer–promoter interaction (looping); thin curved arrows, normal looping; and
thick curved arrows, strong looping. Wavy red lines indicate mRNA.
Using chromatin conformation capture (3C) technol-
ogy [32], a number of risk regions in the 8q24 region
have been shown to form large chromosomal loops to the
promoter of the MYC oncogene [29,30,33–36]. How-
ever, none of these studies has successfully demon-
strated a correlation between the occurrence of these
SNPs and an increase in downstream MYC expres-
sion.MYC expression may be enhanced by these SNPs,
but only at specific times during tumourigenesis, or
only in a particular subset of cells (eg cancer stem
cells). The prostate cancer risk locus at 8q24 also
forms contacts with multiple other genomic loci, some-
times in a cell-type-specific manner, suggesting that the
pathogenic mechanisms of identified susceptibility alle-
les may be MYC-independent [37]. Of note, a num-
ber of susceptibility alleles in the 8q24 region have
been shown to increase the expression of the oncogene
PVT1 [35].
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In cells of the same type but from different individu-
als, SNPs associated with disease (quantitative trait loci;
QTL) affect the variability of TF binding and therefore
can lead to changes in the associated chromatin state.
This would cause local epigenetic variability between
individuals. Recently, Waszak et al and Grubert et al
found that such local chromatin changes due to dis-
tinct genetic variation at TF binding sites are also influ-
enced by the state of other regulatory elements (local,
but also hundreds of kilobases away), and thus affect
large genomic compartments forming regulatory units,
called variable chromatin modules (VCMs) [38]. Vari-
ability within each of these VCMs is mediated by the
spatial chromatin interactions [39], which may affect the
expression of several genes. This might also suggest that
very few apparent ‘epi-mutations’ might be wholly dis-
tinguishable from DNA sequence changes.
Epigenetic signatures of disease
True epi-mutations (ie epigenetic modifications differ-
entially represented in a diseased versus healthy popula-
tion) represent important biomarkers [40], which can be
exploited for patient stratification [41,42], identification
of candidate pathways in disease [43,44], and poten-
tial targets for novel epigenetic editing therapies [45].
Disease-specific DNA methylomes have been identified
in patients with active ovarian cancer [46], distinct forms
of AML [47], colorectal cancer [48], and other diseases.
Thousands of loci have been found to be differentially
enriched for epigenetic signatures marking enhancers
(monomethylation of lysine 4 at histone H3) in a given
colorectal cancer cell sample when compared with nor-
mal crypt cells [49].
EWAS are now underway to identify epi-mutations
associated with disease [50]. These studies are focused
mainly on changes of DNA methylation (methylation
quantitative trait loci – methQTLs) as this is more fea-
sible than histone modification analyses. EWAS have
already identified differentially methylated genomic
regions that may mediate the epigenetic risk of rheuma-
toid arthritis [51] and that may be induced by regular
smoking [52,53]. Intrinsic challenges in epigenetic
analyses include the epigenetic variance between differ-
ent cell types and different developmental stages. New
study design and analysis techniques are now being
developed to help circumvent these issues [54,55].
However, epigenetic variance between single cells of
the same type and development stage may also cause
difficulty in separating true signals from noise [50,56].
Epigenetic regulation in disease
Regulators of DNA modifications
Five different DNA modifications have been described
in eukaryotes. The methylation of number 5 carbon
on cytosine residues (5mC) in CpG dinucleotides
was the first described covalent modification of
DNA [57]. 5mC oxidative intermediates such as
5-hydroxymethylcytosine (5hmC), 5-formylcytosine
(5fC), and 5-carboxylcytosine (5caC) are other metabo-
lites found at CpGs [8]. Recently, a new modification of
eukaryote DNA, N6-methyladenine, was described [9].
In vertebrates, DNA regions with a high density
of CpG dinucleotides form CpG islands. These are
short (∼1000 bp) interspersed CpG-rich and predom-
inantly unmethylated DNA sequences [58]. They are
found in all housekeeping genes and in a proportion
of tissue-specific and developmental regulator genes.
Although DNA methylation is well documented in ver-
tebrates, it is less well understood in other organisms.
In fact, the most commonly studied invertebrate model
organisms, the fly Drosophila melanogaster and the
worm Caenorhabditis elegans, and also the fungus Sac-
charomyces cereviceae all lack DNA methylation [58].
However, in some insects, such as the Hymenoptera
honey bee (Apis mellifera, discussed later), DNAmethy-
lation occurs but is primarily found in gene bodies
affecting the splicing of ubiquitously expressed genes
[59]. In mammals, however, DNA methylation appears
in intergenic regions, where it can, for example, impede
TF binding at promoter regions [58] (Figure 1B).
DNA modifications and disease
Methylated CpG dinucleotides are more sensitive to
mutation by deamination to TpG or CpA [60], and thus
represent a key example where epi-mutations can gen-
erate genetic mutations. Early studies found that CpG
islands are underrepresented in the rodent compared
with the human genome, as they have been eroded dur-
ing evolution [61,62]. These studies suggest that CpG
dinucleotides within the mouse CpG islands were acci-
dentally methylated and mutated to TpG or CpA during
evolution. This could have dramatic consequences when
studying amousemodel where the gene of interest might
be regulated differently compared with its human ortho-
logue. For example, the human α-globin gene is regu-
lated by Polycomb group repressive complexes during
differentiation, whereas the mouse α-globin gene is not
[6]. This led to the development of a humanized mouse
model for the in vivo study of the regulation of the human
α-globin gene expression [63].
Cytosine is methylated by a family of enzymes called
de novo (DNMT1) and maintenance (DNMT3) DNA
methyltransferases. One of the DNMTs, DNMT3A,
is inactivated in related haematological malignancies
[64] such as myelodysplastic syndromes (MDS) [65]
and AML [66]. Around 30% of MDS cases progress
to acute myeloid leukaemia (AML) [67]. Interestingly,
loss-of-function mutations of DNMT3A that do not
affect its catalytic domain disrupt the formation of a
tetramer with another protein, DNMT3L [68,69]. These
mutations have a dominant-negative effect, which
prevents the wild-type protein from functioning nor-
mally [68,69]. The ten–eleven translocation (TET 1–3)
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 238: 333–344
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family of proteins are the mammalian DNA hydroxy-
lases responsible for catalytically converting 5mC to
5hmC [70]. Loss-of-function of TET2 and DNMT3A
seems to be a primary event during leukaemogene-
sis [71]. Disruption of normal methylation patterns
in colorectal cancer cells correlates with underex-
pression of tumour suppressor genes (Figure 1B) and
overexpression of oncogenes (Figure 1I) [48].
Regulators of histone modifications
The opposing effects of the Polycomb group (PcG,
associated with gene repression) and Trithorax group
(associated with gene activation) remodelling proteins
regulate many cellular decisions in stem cell biology,
development, and cancer. Histone H3 trimethylated
at lysine 27 (H3K27me3) is generated by Polycomb
repressive complex 2 (PRC2) and involves a ‘reader’,
EED, which recognizes a pre-existing modified histone
(H3K27me3), and a ‘writer’, methyltransferase EZH2,
which modifies the histones nearby [72]. Histone
H3K27 methylation is removed by ‘erasers’, which
prevent the maintenance/propagation of this modifi-
cation. Three histone demethylases, UTX (KDM2A),
UTY, and JMJD3 (KDM2B), have been reported to
remove H3K27me3 [73,74]. Disease-causing muta-
tions may affect the histone genes themselves, or the
enzymes (readers, writers, and erasers) regulating the
post-translational modifications of their products.
In contrast to DNA methylation, some histone mod-
ifications and their functions are conserved from yeast
to human (eg H3K4me3), but the families of enzymes
catalysing the addition or removal of these modifica-
tions have expanded during evolution. For example, one
single protein catalyses the deposition of H3K4me3 in
yeast (Set1, part of the COMPASS complex), whereas
in mammals up to six (SET1B, SET1B, MLL1, MLL2,
MLL3, and MLL4) enzymes have been reported [75].
This expansion follows the shift from unicellular to mul-
ticellular organisms, although the expression of each
enzyme is not necessarily tissue-specific, which explains
why redundancy is often observed. PcGs, involved in
the deposition of histone marks (H2AK118ub for PRC1
and H3K27me3 for PRC2) associated with transcrip-
tional repression, were first identified in Drosophila
melanogaster [76]. The mechanism of PcG recruitment
in Drosophila is different as these are recruited to spe-
cific DNA sequences called polycomb repressive ele-
ments [76], whereas in mammals these complexes are
recruited by CpG islands [77,78].
Histone modification regulators in disease
EZH2 is the most frequently mutated PRC2 compo-
nent in cancer. However, both gain-of-function [79] and
loss-of-function [80–83] mutations have been observed
in lymphoma and leukaemia, respectively (reviewed
in refs 84 and 85). Certain evidence suggests that
genomic loss or hypoxia-induced down-regulation of
microRNA-101 (miR-101) is the cause of EZH2 over-
expression in many solid tumours [86–89].
As epigenetic regulators target vast numbers of genes
influencing their transcription rates, it is unsurpris-
ing that both inactivation and hyperactivation of these
enzymes can lead to disease, depending on the tissue
type and the developmental stage. Other genes involved
in cancer have also been found to have opposing roles in
different tissues. This is the case for NOTCH1, encoding
a transmembrane receptor, which has been described as
an oncogene in leukaemia [90] and a tumour suppres-
sor gene in solid tumours [91,92]. Mutations affecting
protein–protein interactions may explain these oppos-
ing effects. For example, certain missense mutations of
the tumour suppressor p53 (TP53) can exhibit oncogenic
activities with a dominant-negative effect achieved by
the oligomerization of the mutant and the wild-type pro-
teins [93,94].
Chromosomal translocations, originally identified in
leukaemic cells, can also affect epigenetic regulators
by creating novel fusion proteins, with different func-
tions compared with the wild-type protein (Figure 1M).
Almost all leukaemias and lymphomas harbour translo-
cations (reviewed in ref 95). Chromosomal rearrange-
ments affecting the Trithorax group MLL gene occur in
over 70% of infant leukaemia cases [96]. The resulting
fusion proteins cause overexpression of a number of dif-
ferent target genes despite the fact that most of these
rearrangements cause a deletion of the catalytic SET
domain of MLL [96,97]. One mechanism of this deviant
gene activation by MLL fusion proteins is the aber-
rant recruitment of DOT1L, a H3K79 histone methyl-
transferase, associated with transcriptional elongation
[96,98–101].
Sequence conservation is high in the Jumonji C
(JmjC) catalytic domain amongst the histone H3K27
demethylases, UTX (KDM2A), UTY, and JMJD3
(KDM2B) (Figure 2) [102,103]. Other domains involved
in protein–protein interactions may be important for
substrate specificity and segregate the function or targets
of these enzymes. For example, in T-ALL, UTX func-
tions as a tumour suppressor, whereas JMJD3 works as
an oncoprotein, despite their common enzymatic activ-
ity [104]. Histone H3K27 demethylases have several
functions besides their enzymatic activities, such as
nucleosome depletion [105] or transcription elongation
[106]. Mutations seen in cancer may cause quantitative
changes to overall expression, or qualitative changes that
enhance or repress specific domain functions. Figure 2
depicts the UTX gene and its inactivating mutations
found in T- and B-cell acute lymphoblastic leukaemia
(T-ALL and B-ALL), and also in chronic myelomono-
cytic leukaemia (CMML) [107]. From this diagram it
is not clear if the tumour suppressor activity of UTX
depends on its demethylase activity as some mutations
(affecting the TRP domain) leave the catalytic domain
intact. Also, the sequence conservation within this
family of enzymes makes it difficult to design specific
inhibitors against each individual H3K27 demethylase
(eg cross-reactivity of GSK-J3/GSK-J4 for JMJD3 and
UTX) [108]. Moreover, epigenetic regulators do not
target just histones, but other proteins also [109].
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 238: 333–344
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Figure 2. Mutations of the UTX gene in leukaemia. The UTX (ubiquitously transcribed X chromosome tetratricopeptide repeat protein) gene
contains 29 exons (black boxes) that encode a 1401-amino acid (aa) protein with a molecular weight of 154 kDa. The amino-terminal
region shows six tetratricopeptide repeat (TRP) domains (indicated in orange) and one JmjC domain (aa 1095 to 1258) which contains a
catalytic histidine (His1146) (indicated in red). Blue circles depict frameshift mutations (FS) in the JmjC domain in paediatric T-ALL [177],
and white circles depict an in-frame deletion, a splice acceptor site mutation, and a missense mutation in adult T-ALL [104]. Additional
T-ALL patients have been identified with mutations (brown circles) in the same hotspot region of the JmjC domain [120]. These include
three frameshift (Val1113-FS) and two in-frame insertions/deletions. Other mutations have been found in paediatric B-ALL (green circles),
with one frameshift, two missense, and one nonsense mutations in the JmjC domain, and an additional missense mutation between the
TRP and JmjC domains [178]. Other mutations have been found in CMML (purple circles) [107,179] and AML (black circle) patients. A
deletion was also detected in a patient with MDS [180]. In patients with an inactivated catalytic domain, the mutant protein may have a
dominant-negative activity as the protein-interacting TRP domain at the N-terminus is preserved. This may allow the mutant protein to
still interact with other proteins, and thus compete with the wild-type protein (UTX for female and UTY for male) expressed by the other
chromosome. Note that this gene also produces many splice variants.
Histone variants in disease
As described above, histones are the building blocks
of nucleosomes, which are involved in chromatin
packaging. Many histone variants exist, expanding the
traditional roles of histones to include mechanisms
such as DNA repair and maintenance of genomic sta-
bility [110]. Histone H3.3 is one such variant, which is
essential for mouse development, genomic stability, and
normal heterochromatin function [111]. The first muta-
tions linking human disease to histone variants were
identified in the genes H3F3A and HIST1H3B encoding
H3.3 and canonical H3.1, respectively [112,113]. These
recurrent gain-of-function mutations, affecting residues
at or close to the position where H3K27me3 occurs,
have been found in approximately 50% of paediatric
high-grade gliomas [112,113]. One of these mutations,
K27M in H3.3, is a dominant-negative inhibitor of
H3K27me2/3 deposition, reducing global H3K27me2/3
on wild-type H3.1 and H3.3 histones [114–117].
H3.3-K27M prevents H3K27me2/3 deposition through
direct interaction with, and inhibition of, PRC2 compo-
nents [115,116]. The global reduction of H3K27me3 is
concurrent with changes in DNA methylation patterns
specific to tumours from H3.3-K27M patients, leading
to distinct changes in gene expression [115].
Conclusion
To date, 125 genes with driver mutations for cancer
have been discovered, and nearly half of them encode
epigenetic regulators [118]. The high frequency of these
mutations reflects the critical role of epigenetics in
disease. Disease-specific epigenome signatures suggest
that epigenetics plays an important role even in cancers
where epigenetic regulators have not been mutated
[49]. These changes in the epigenetic landscape are
strongly correlated with transcriptional changes in
cancer driver genes [48]. Importantly, the potency
of these epigenetic regulators makes them excellent
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therapeutic targets; modulation of their activity by use
of inhibitors could potentially reset the epigenome to a
‘normal’ state. For instance, inhibitors of DNA methyl-
transferases such as azacitidine (5-azacytidine) and
decitabine (5-aza-deoxycytidine; DAC) lead to DNA
hypomethylation and have shown promising results
in the treatment of MDS [119]. Even when a tumour
suppressor gene is missing, targeted inhibition of its
antagonist can potentially reset epigenetic imbalances
and mediate beneficial responses [120]. To illustrate,
loss-of-function of a H3K27 demethylase creates an
imbalanced preponderance of H3K27me3 modifica-
tions in a cell. These effects could be minimized by the
use of a large number of promising EZH2 inhibitors
(DZNep [121], EI1 [122], GSK126 [123,124], GSK926
[125], GSK343 [124], EPZ005687 [126], CPI-169
[127], UNC1999 [128,129], and others [130]). A list of
current inhibitors under development for all epigenetic
regulators is beyond the scope of this review, but all
the current epigenetic therapies and their relevance
to leukaemia can be found elsewhere [131]. We must
still also consider that during cancer progression, cells
accumulate mutations that generate genetic and/or epi-
genetically distinct subclones displaying both genotypic
and phenotypic heterogeneity [132]. Such heterogeneity
presents another challenge to treatment.
The question still remains: is a genetic mutation
always required, or are pure epi-mutations sufficient
to cause a disease? Studies across many species have
shown how environmental factors can directly influ-
ence phenotypes through epigenetic mechanisms. For
example, queen honey bees are fed with royal jelly
throughout their lifetime, with effects involving DNA
methylation changes [133], gene expression changes
[134], and phenotypic differences including increases
in size and longevity [135], when compared with their
worker bee siblings (reviewed in ref 136). Interest-
ingly, the royal jelly contains a histone deacetylase
inhibitor [137,138] that significantly increases lifespan
in Drosophila [135]. In humans, the study of monozy-
gotic twins (genetically identical individuals) with
discordant diseases represents an excellent system with
which to identify environmental causes of epi-mutations
because potential confounders (genetic factors, age,
gender, maternal effects, cohort effects, etc) can be con-
trolled [139]. For example, studies ofmonozygotic twins
showed that epigenetic differences arise during their
lifetimes [140], and that twins rarely develop the same
disease [141,142]. Although different somatic mutations
can accumulate over time in these individuals, envi-
ronmental factors causing epigenetic changes may be
important in disease. A recent study on a pair of identical
twins discordant for common variable immunodefi-
ciency (CVID) revealed that differential DNA methyla-
tion was associated with deregulation of genes involved
in maturation of B-cells, but without considering poten-
tial somatic mutations that may have occurred during
adult life [143]. Overall, most discordant monozygotic
twin studies seem to involve autoimmune, psychiatric,
and neurological diseases, but also different types of
cancer [139]. The importance of the environment during
adulthood has been shown in a recent EWAS, which has
identified differentially methylated CpGs in smokers
versus non-smokers that could potentially be associated
with increased breast cancer risk [53].
Epigenetic modifications also vary during lifespan
and between different tissues, making disease-causing
epi-mutations difficult to separate from normal vari-
ation. It is therefore important to ensure that age-
and tissue-matched reference epigenomes are available
for comparison. In some cases, epi-mutations might
be inherited through the germline, suggesting a pos-
sible existence of purely epigenetically transmissible
diseases. Transgenerational epigenetic inheritance stud-
ies have been described in plants [144], invertebrates
[145], and mammals [146,147], usually using changes
of diet conditions as a model (reviewed in refs 148 and
149). However, these studies are mostly descriptive and
require more mechanistic insights [150].
SNPs in enhancers and epi-mutations have been
strongly correlated with disease risk in many cases
[51,53,151,152]. However, correlation does not equate
to causation. Although effects of mutations in coding
sequences are relatively easy to investigate, SNPs
located in enhancer sequences, and associated with
disease, are more difficult to validate. For example, the
previously GWAS-identified SNPs in obese patients are
located in the first intron of the FTO gene. Smemo et al
recently published that this intron acts as an enhancer,
not for the FTO gene but for another gene, IRX3,
located 500 kb away, thus revealing the role of IRX3
(and not FTO) in obesity [153]. Many excellent studies
mentioned in this review and beyond have aimed to
dissect the mechanism by which an enhancer SNP or
deletion may lead to disease, but the true ‘gold stan-
dard’ technique would be to replicate the mutation in
vivo and examine the results. Classical gene targeting
techniques have achieved this in some cases [154] but
recently described genetic editing tools could make
a rigorous characterization of these mutations more
widely achievable [155]. Similarly, the use of targeted
epigenetic editing techniques [156,157] will expand the
ability of epigeneticists to investigate the phenotypes of
epi-mutations.
These recently described genome and epigenetic edit-
ing techniques could be used in the clinic to completely
reset a disease-causing mutation in a patient. Certainly,
many studies are already underway investigating the
use of genetic editing techniques in treating diseases
such as acquired immune deficiency syndrome (AIDS)
[158] and X-linked severe combined immunodeficiency
(SCID-XI) [159] (reviewed in ref 160). Epigenetic
editing, although in its infancy, is proving extremely
effective and could potentially be used as a means of dis-
ease treatment [45,157]. However, particularly in cancer
treatment, where mutation load can reach into the hun-
dreds in certain tumours [118], it would be extremely
difficult to correct every driver mutation in every cell.
Meanwhile, the debate continues over the ethical use of
genetic editing techniques as a form of disease treatment
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for humans [161]. The use of inhibitor drugs in a clin-
ical setting to target the effects of these mutations still
remains a much more realistic option for the treatment
of many cancers. As some of the proteins targeted by
these drugs can have opposing effects (oncogene versus
tumour suppressor) in cells from the same tissue, it is
important to understand the biology of themutations and
the function of these proteins in each lineage to identify
the tumourigenic pathways that they may regulate.
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